Crossmark

Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials

Crossref DOI link: https://doi.org/10.1038/s41380-026-03543-1

Published Online: 2026-03-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Damiani, Stefano https://orcid.org/0000-0002-5235-0788
Stefanelli, Riccardo

Fortea, Lydia https://orcid.org/0000-0001-6778-2316
D’Imperio, Aldo https://orcid.org/0009-0000-6928-8477
Calò, Matteo

Casarini, Francesco

Crippa, Andrea

Esposito, Cecilia Maria https://orcid.org/0000-0002-4610-0686
Leggi, Roberto

Orlandi, Marika https://orcid.org/0000-0003-2783-5262
Patron, Sara

Peviani, Alessandro

Piccolo, Alessandro

Provenzani, Umberto

Santilli, Fabrizio

Spallarossa, Cecilia

Papanastasiou, Evangelos

Cella, Matteo

Patel, Rashmi https://orcid.org/0000-0002-9259-8788
Solmi, Marco https://orcid.org/0000-0003-4877-7233
Galderisi, Silvana

Leucht, Stefan https://orcid.org/0000-0002-4934-4352
Stahl, Daniel https://orcid.org/0000-0001-7987-6619
Radua, Joaquim https://orcid.org/0000-0003-1240-5438
Fusar-Poli, Paolo
License Information

Text and Data Mining valid from 2026-03-23

Version of Record valid from 2026-03-23
More Information

Article History

Received: 7 September 2025

Revised: 11 February 2026

Accepted: 10 March 2026

First Online: 23 March 2026

Competing interest

: RP has participated in Scientific Advisory Boards for Boehringer Ingelheim and Teva, has received grant funding from Janssen, and has received consulting fees from Holmusk, Akrivia Health, Columbia Data Analytics, Clinilabs, Social Finance, Boehringer Ingelheim, Bristol Myers Squibb, Supernus, Teva and Otsuka. EP is currently employed at the HMNC Holding GmbH. MS received honoraria/has been a consultant for Angelini, AbbVie, Boehringer Ingelheim, Lundbeck, Otsuka.

Document is current

Any future updates will be listed below